Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Chemoembolization for Lung Tumors

Phase 1

Completed

Conditions: Lung Metastases
Pleural Metastases
Mediastinal Metastases
Endobronchial Metastases

Interventions: Procedure: Chemoembolization
Drug: Mitomycin C
Drug: Lipiodol
Drug: Embospheres

First Posted Date: 2019-12-16

Last Posted Date: 2022-04-22

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 10

Registration Number: NCT04200417

Locations: 🇺🇸
Memoral Sloan Kettering Monmouth (Consent only), Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center @ Commack (Consent Only), Commack, New York, United States
🇺🇸
Memoral Sloan Kettering Westchester (Consent only), Harrison, New York, United States

and more 1 locations

GDC-0084 With Radiation Therapy for People With PIK3CA-Mutated Solid Tumor Brain Metastases or Leptomeningeal Metastases

Phase 1

Active, not recruiting

Conditions: Leptomeningeal Metastasis
Brain Metastases

Interventions: Drug: GDC-0084
Radiation: whole brain radiation therapy radiation

First Posted Date: 2019-12-10

Last Posted Date: 2024-04-17

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 21

Registration Number: NCT04192981

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge (Consent only), Basking Ridge, New Jersey, United States
🇺🇸
University of Washington (Data Collection AND Data Analysis), Seattle, Washington, United States
🇺🇸
Memorial Sloan Kettering Cancer Center (All protocol activities), New York, New York, United States

and more 6 locations

Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment

Phase 1

Recruiting

Conditions: Non-Muscle Invasive Bladder Cancer (NMIBC)

Interventions: Drug: Bacillus Calmette-Guérin (BCG)
Drug: Gemcitabine

First Posted Date: 2019-11-27

Last Posted Date: 2024-04-02

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 68

Registration Number: NCT04179162

Locations: 🇺🇸
Hartford Healthcare (Data Collection), Hartford, Connecticut, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States

and more 5 locations

Safety of Lower Scalp Cooling Temperature to Prevent Hair Loss From Chemotherapy in Breast Cancer Patients

Not Applicable

Active, not recruiting

Conditions: Breast Cancer Stage I
Breast Cancer
Breast Cancer Stage III
Breast Cancer Stage II

Interventions: Device: PAXMAN Scalp Cooler

First Posted Date: 2019-11-27

Last Posted Date: 2024-06-05

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 34

Registration Number: NCT04180579

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma

Phase 2

Active, not recruiting

Conditions: Multiple Myeloma
Plasmacytoma of Bone
Plasmacytoma

Interventions: Drug: CC-486
Drug: Lenalidomide
Radiation: Radiation Therapy

First Posted Date: 2019-11-22

Last Posted Date: 2024-12-04

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 21

Registration Number: NCT04174196

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center @ Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 4 locations

Communication Training for Caregivers In Advanced Care Planning

Completed

Conditions: Advanced Care Planning
Primary Malignant Brain Tumors

Interventions: Other: Questionnaires
Other: Enhanced usual care
Other: Communication training Part 1 (no longer recruiting)
Other: Communication training Part II

First Posted Date: 2019-11-21

Last Posted Date: 2024-08-26

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 49

Registration Number: NCT04171895

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

PET and MRI Imaging of Brain Tumors Using [18F]PARPi

Early Phase 1

Active, not recruiting

Conditions: Brain Cancer
Brain Tumor

Interventions: Diagnostic Test: PET/MR with [18F]PARPi
Drug: [18F]PARPi

First Posted Date: 2019-11-21

Last Posted Date: 2024-12-18

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 5

Registration Number: NCT04173104

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Bleeding in Critically Ill Children With Underlying Oncologic Diagnoses

Completed

Conditions: Bleeding
Cancer

First Posted Date: 2019-11-20

Last Posted Date: 2023-10-19

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 93

Registration Number: NCT04170231

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

The Use of Nanoparticles to Guide the Surgical Treatment of Prostate Cancer

Phase 1

Recruiting

Conditions: Prostate Cancer

Interventions: Drug: (64Cu)-labeled PSMA-targeting particle tracer, or 64Cu-NOTA-PSMAi-PEG-Cy5.5-C' dots
Diagnostic Test: PET/MRI
Other: Blood and urine sampling
Procedure: laparoscopic radical prostatectomy and bilateral pelvic LN dissection or a salvage lymph node dissection

First Posted Date: 2019-11-19

Last Posted Date: 2024-02-06

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 10

Registration Number: NCT04167969

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors

Phase 2

Recruiting

Conditions: Rectal Adenocarcinoma
Clinical Stage: Stage II (T3-4, N-)
Stage III (Any T, N+)
Solid Tumor
Solid Tumor, Adult

Interventions: Drug: TSR-042 or Dostarlimab
Drug: capecitabine or 5-FU
Radiation: Intensity Modulated Radiation Therapy (IMRT)

First Posted Date: 2019-11-18

Last Posted Date: 2024-04-23

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 200

Registration Number: NCT04165772

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge - Limited Protocol Activities, Basking Ridge, New Jersey, United States
🇺🇸
New York Cancer and Blood Specialists, Babylon, New York, United States
🇺🇸
Hartford Healthcare (Data Collection), Hartford, Connecticut, United States

and more 8 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy